Just when you think you know what to expect from the FDA, they go and shake things up.

This is a developing story, but the implications for companies involved in clinical trials are clear.

Both European and US regulators expect data integrity when it comes to clinical data and are increasingly willing to cite problems found during inspections.  

Rethink What You “Know”

We all “know” FDA doesn’t cite Part 11 in 483s, right?

Well, maybe.

FDA podium-speak has been that the software inspectors use to track findings does not allow Part 11 citations, that they must go back to predicate rules instead.

However, it is time to rethink that.

Until now, the only example we’ve seen of a Part 11 citation in clinical trials was the 2016 inspection of Clinical Investigator Dr. Cassandra Curtis that resulted in a Warning Letter.

Dr. Curtis’ 483 stated, “Electronic records are used, but they do not meet requirements to ensure they are trustworthy, reliable and generally equivalent to paper records.” In this case, the observation was aimed at discrepancies in the electronic medical records used by Dr. Curtis to record source data for clinical trial subjects.

Immunomedics 483: A Sign Of Things To Come?

In the most recent Part 11 example, FDA cited Immunomedics, as the Sponsor of clinical trials, for using electronic records that “do not meet systems validation and audit trail requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.”

The 483 goes on to state, “Specifically, Immunomedics utilized the computer program (b)(4) to record data from each of the clinical site’s (sic) Case Report Forms (CRFs), including Adverse and Serious Adverse Events, from inception through May of 2017 for the reporting of clinical data to FDA. The program was not validated, and an audit trail to monitor use was not implemented.”

It is not clear yet what kind of system was at issue. Possibilities include:

  • Electronic Data Capture (EDC) system deployed by Immunomedics to the clinical sites
  • System used at Immunomedics to transform data recorded by the clinical sites on paper CRFs into usable electronic records
  • System used at Immunomedics to extract and store clinical data from an EDC system

Is FDA Catching Up?

21 CFR Part 312 comes “straight from the 80s,” and does not account for the complexities of today’s clinical trials.

Is FDA following the lead of European regulators and taking the data integrity problems they see at investigator sites back to the sponsor? Is FDA finding ways to deal with “CROs” that aren’t CROs? Or is FDA learning to address the complexities of how sponsors manage clinical data from multiple, disparate sources?

We’ll share more as we learn more in this developing story…

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

Secure your spot for this informative 1-hour webinar on building a culture of quality by learning from past mistakes.

If you can’t make the webinar, no problem. Register and we will send you a post-show recording.

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented on Tuesday, March 30, 2021
by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Download the slide deck and video of this informative 1-hour webinar on the common challenges small pharma firms face when developing a QMS.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
  • Recent enforcement trends involving the Quality Unit
  • Impact of the COVID-19 pandemic

Download the Special Report


In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.